United States: New York

Firms: litigation

  • Cravath, Swaine & Moore LLP 
  • Desmarais LLP 
  • Gibson Dunn & Crutcher LLP
  • Goodwin Procter LLP
  • Kirkland & Ellis LLP
  • Paul Hastings LLP
  • Paul Weiss Rifkind Wharton & Garrison LLP
  • Quinn Emanuel Urquhart & Sullivan LLP
  • Arnold & Porter Kaye Scholer LLP
  • Axinn, Veltrop & Harkrider LLP 
  • Baker Botts LLP
  • Dechert LLP
  • Fenwick & West LLP
  • Greenberg Traurig LLP
  • King & Spalding LLP
  • Latham & Watkins LLP
  • Mayer Brown
  • Milbank LLP
  • Sidley Austin LLP
  • Venable LLP
  • White & Case LLP 
  • Wilmer Cutler Pickering Hale and Dorr LLP
  • Alston & Bird LLP
  • Fish & Richardson
  • Haug Partners LLP 
  • Hughes Hubbard & Reed LLP
  • Hunton Andrews Kurth LLP
  • Jones Day
  • Leason Ellis LLP
  • O’Melveny & Myers LLP
  • Pearl Cohen Zedek Latzer Baratz
  • Perkins Coie LLP
  • Proskauer Rose LLP
  • Robins Kaplan LLP
  • Ropes & Gray LLP
  • Shearman & Sterling LLP 
  • Skadden Arps Slate Meagher & Flom LLP
  • Steptoe & Johnson LLP
  • Sullivan & Cromwell LLP
  • Weil Gotshal & Manges LLP
  • Winston & Strawn LLP 

Firms: prosecution

  • Baker Botts LLP
  • Ballard Spahr LLP
  • Dechert LLP
  • Fay Kaplun & Marcin LLP
  • Fish & Richardson
  • Fox Rothschild LLP 
  • Greenberg Traurig LLP
  • Haley Guiliano LLP
  • Leason Ellis LLP
  • Norton Rose Fulbright
  • Pearl Cohen Zedek Latzer Baratz
  • Steptoe & Johnson LLP

Firms: transactions

  • Highly recommended
  • Cravath, Swaine & Moore LLP 
  • Skadden Arps Slate Meagher & Flom LLP
  • Sullivan & Cromwell LLP
  • Weil Gotshal & Manges LLP
  • Recommended
  • Arnold & Porter Kaye Scholer LLP
  • Baker Botts LLP
  • Baker McKenzie
  • Davis Polk & Wardwell LLP
  • Dechert LLP
  • Kirkland & Ellis LLP
  • Leason Ellis LLP
  • Mayer Brown
  • Pearl Cohen Zedek Latzer Baratz
  • Proskauer Rose LLP
  • Shearman & Sterling LLP 
  • Venable LLP
  • White & Case LLP 

Alston & Bird LLP

Alston & Bird puts wide-ranging patent expertise at the fingertips of clients: when they need prosecution services, it calls to action advanced technical specialists with an affinity for IP value creation; and when they need to enforce patent rights or defend them against commercial competitors, it deploys seasoned litigators to the battlefield. One such is trial lawyer Natalie Clayton, who provides superb captaincy to the life sciences patent litigation group. She has extensively represented Merial (now Boehringer Ingelheim Animal Health) in the International Court of Arbitration, district courts and the PTAB. Wherever a case takes her, she gets the job done, leveraging sparkling advocacy skills and profound patent and regulatory know-how.

Arnold & Porter Kaye Scholer LLP

Arnold & Porter thrives in the cut and thrust of pharmaceutical and biotechnology patent litigation and is a go-to for representation in the most complex and highest-exposure cases. One look at its line-up in New York settles any nerves: David Barr, Daniel Reisner, Aaron Stiefel and Daniel DiNapoli bring a tremendous amount of experience to the table and have seen and done it all before. Coming in for praise, Barr is a “detail-oriented lawyer and deep thinker who is excellent on the technical aspects of his craft”. He recently linked up with DC’s Matthew Wolf to win a jury trial for Hologic and Grifols against bioMerieux regarding blood-screening assays. He and Reisner – as well as Wolf and Silicon Valley partner Deborah Fishman – also secured a major victory for Sanofi and Regeneron against Amgen, which had sought billions in damages and a permanent injunction against the sale of Sanofi and Regeneron’s cholesterol-reducing drug Praluent. Stiefel and DiNapoli, meanwhile, have continued their sterling representation of Pfizer against generic challenges to multiple blockbuster drugs, including Xeljanz, Viagra and Celebrex.

Axinn, Veltrop & Harkrider LLP 

When pharmaceutical and biotechnology companies need to enlist special forces support, many dial up Axinn’s patent trial lawyers, who form one of the most dynamic groups in the country. This is piloted to win after win by head of the intellectual property and Food and Drug Administration (FDA) practices Chad Landmon, an agile, business-focused advocate with exceptional regulatory knowledge. Lately, he has been defending Zydus Pharmaceuticals in a Hatch-Waxman infringement action brought by Boehringer Ingelheim Pharmaceuticals involving three drug products that improve glycaemic control in sufferers of type 2 diabetes; as this case confirms, Landmon excels at mounting aggressive challenges to patent validity. Managing partner Matthew Becker has a talent for undermining plaintiffs’ cases through astute cross-examination of witnesses, which has proved pivotal in many of his wins. Together with Landmon, he recently went out to bat for Norwich Pharmaceuticals against Salix Pharmaceuticals in a District of Delaware case involving 23 patents and more than 460 asserted claims. A huge asset given his in-house experience, David Silverstein is also critical to the ensemble’s success: having previously overseen all aspects of litigation at Par Pharmaceutical, he understands what clients are seeking to achieve through litigation.

Baker Botts LLP

Baker Botts is home to multiple individuals with multiple IAM Patent 1000 rankings, which attests to the well-roundedness with which they – and the firm – practise patent law. Paul Ragusa, for example, is recommended for prosecution, transactions and litigation, and is the full package for clients such as Columbia University and Ethypharm. Steve Lendaris and Daniel Hulseberg, meanwhile, are tipped for both prosecution and transactions. Lendaris provides strong leadership to the life sciences IP group and gives fulsome support to industry leaders on patent protection and diligence matters, drawing judiciously on Baker Botts’ deep technical bench. Due diligence maestro Hulseberg acquits himself with distinction on behalf of one of the world’s largest global healthcare companies; his instinct for assessing competitive landscapes and identifying strategic opportunities is second to none. One of relatively few lawyers to be highlighted for prosecution and litigation, global IP chair Robert Scheinfeld is key to the firm’s Hitachi relationship: he and fellow trial lawyer Robert Maier handle the conglomerate’s 1,000-plus patent portfolio and fight its corner in litigation. A sought-after opinion giver and counsellor, Neil Sirota also demonstrates versatility: in his focused domain of litigation, he and Maier have been trusted allies of Samsung Electronics for many years. Trial and appellate lawyer Jen Tempesta completes the line-up. Together with Scheinfeld, she recently won a major victory for Mastercard International against which Alexsam asserted failure to pay licence royalties; the court ruled in favour of Mastercard on all issues, including patent claim construction and interpretation of the agreement, and found that Alexsam was judicially estopped from demanding licensing royalties under the agreement.

Baker McKenzie

Baker McKenzie has its flag firmly planted in the New York IP market, courtesy of James Blank, an experienced lead patent trial counsel with a high-profile international following. Since he arrived in 2019, and while continuing to litigate at the elite level, he has also leaned into the firm’s global patent prosecution practice and manages matters for Sientra, an innovator in plastic surgery implantable devices and others, working alongside DC colleague Richard Wells. The worldwide coverage that Baker McKenzie can afford is a real boon for those seeking far-reaching protection.

Ballard Spahr LLP

Recommended in the IAM Patent 1000’s New York rankings for the first time this year, Ballard Spahr has a star practitioner in the city in Kenneth Sonnenfeld, a pharmacology PhD with decades of experience at the cutting edge of development in the life sciences. Reflecting on its relationship with him, one client comments: “We have had the pleasure of working with Ken for many years, during which he has unequivocally become our most trusted source for IP advice. Ken understands our business and risk tolerance, and has always ensured his advice is centred on the things that are most relevant and important to us. He has never failed to deliver on an assignment in a timely manner or with less than impeccable quality work. We treasure our relationship with him.” A Swiss Army knife of a practitioner – he is recommended on all three practice area tables in the guide – he provides high-calibre support on prosecution, licensing and disputes matters. He came on board from King & Spalding in January 2020 alongside Margaret Brivanlou, a molecular biology PhD who also has the magic touch when it comes to counselling on strategy and extracting IP value. They have fitted in well at a firm that prioritises a well-rounded, commercially tuned patent service.

Cravath, Swaine & Moore LLP 

Otherworldly in terms of sophistication of representation and quality of service, Cravath is a repository of trust for global innovators when there are tough, multi-threaded patent, antitrust and licensing disputes to be fought or seismic deals to be signed, sealed and delivered. Its trial and transactional lawyers draw on incredibly broad legal, strategic and mercantile horizons to devise creative solutions to the problems that keep in-house counsel and business leaders awake at night. The first name on the litigation team sheet is Keith R Hummel, who does an exemplary job developing strategy for disputes, communicating options, preparing clients when they need it and, above all, executing on their objectives: “Keith is an unbelievably hard worker who makes himself available at clients’ convenience and is one of the best lawyers in any practice area.” There are no sharp elbows at Cravath and plenty of highly effective collaboration is in evidence: Hummel and Sharonmoyee Goswami connect brilliantly together, as they did recently on behalf of Amgen. Goswami became a partner in January 2020: having joined the firm as a summer associate a decade ago, she has risen through the ranks thanks to her exceptional command of the law, technical dexterity, intellect and positivity. Evan R Chesler and Richard J Stark – whose representation of Qualcomm in IP, antitrust and contract actions brought by Apple and resolution thereof is the stuff of legend – have reunited on behalf of short-form streaming start-up Quibi in consolidated patent and trade secret litigation against Israeli technology company JBF Interlude 2009. With them on this is David R Marriott, an American College of Trial Lawyers fellow who is as seasoned as they come. On the transactional side, the venerable David J Kappos continues to set standards of excellence and thought leadership that are virtually impossible to meet. In one recent highlight, he is acting for Mylan in its pending $50 billion combination with Upjohn, a division of Pfizer, which involves many complex IP licensing issues.

Davis Polk & Wardwell LLP

Davis Polk is a go-to for IP-intensive transactions: blue-chip patrons take confidence from the brokering experience and industry knowledge of top specialists Frank Azzopardi and David Bauer, who preside over high-value deals of all kinds. Practice head Azzopardi is a veteran of transactions that have helped to shape the consumer products and retail, energy and industrial solutions, airline and transportation and high-technology sectors; while biosciences PhD Bauer has done the same in the pharmaceutical and biotechnology space. They set the pace, but rely on outstanding support from a diverse, highly trained group of colleagues.

Dechert LLP

Dechert’s elite life sciences prosecution and counselling practitioners work hand in glove with its crack litigators to provide pharmaceutical and biotechnology innovators with total support throughout all phases of the patent lifecycle. In terms of USPTO-facing work and portfolio development, the key names to know in New York are synthetic organic chemistry PhD Carl Morales and strategic IP planning maestro Samuel Abrams. Morales has had a busy time of it on the transactions front lately, advising Royalty Pharma – a purchaser of biopharmaceutical royalties – in connection with numerous deals; he also conducts high-level prosecution of patents for drug products that are FDA approved or in a state of near approval. Abrams is constantly on call for multinationals and academic institutions as they procure and commercialise IP assets; a former member of the patent departments at Procter & Gamble and Merck, he has an insider’s view of the innovation process. On the litigation side, Katherine Helm, Noah Leibowitz and Stephen Rabinowitz form a formidable contingent of trial lawyers. An absolute dynamo who makes significant contributions both to the Dechert practice and to the wider IP community, Helm never fails to impress. Eli Lilly and Company recently benefited from her trial and post-grant prowess in an infringement action brought by Genentech over Eli Lilly’s blockbuster immunosuppressant antibody therapy Taltz – a case which involved one of the few life sciences post-grant reviews, and one of the first such challenges to apply written description and enablement law to antibody technology. Leibowitz aids clients in many meaningful ways as a first-chair trial counsel and deal lawyer; he is recommended in the guide for both litigation and transactions. Rabinowitz is among the most scientifically gifted litigators in the country.

Desmarais LLP 

Senior general counsel hail Desmarais as “unparalleled in terms of expertise and client service when it comes to high-stakes litigation”. The richly resourced team lives to fight mission-critical patent, trade secret, antitrust and other technology-intensive cases for household names, and has cracked the code of winning trials – on both sides of the ‘v’ – in all key forums in the United States. Meanwhile, its flexible and innovative fee arrangements further set it apart. Repeating its stellar showing in the previous edition, it once again has several new faces in the IAM Patent 1000 this year in Bindu Donovan, Todd L Krause and Yung-Hoon (Sam) Ha, which attests to the sheer depth of the squad. Donovan and biological sciences PhD Krause are anchors of the life sciences practice and poised advocates for drug originators in Hatch-Waxman litigation and other pharmaceutical and biotechnology disputes. Together, they recently represented patent holder Actelion Pharmaceuticals in a case against Zydus Pharmaceuticals and Cadila Healthcare relating to a treatment for pulmonary arterial hypertension. Materials science and engineering PhD Ha is the team’s top post-grant specialist. As a key ingredient of its success, the firm puts leanly configured but rigorously cooperative teams onto the playing field – a model which sees those already named join up with the likes of gold-ranked John M Desmarais and Paul A Bondor, both of whom are talismanic figures for the group. “John is the best in the profession – a wise, analytical, clear-thinking lawyer with great courtroom presence, who identifies the key issues that lawyers elsewhere miss. He has built a group with tremendous depth and which gets superb results in case after case.” He and likeminded lawyer Bondor are frequently hired to take over matters – as they were when Johnson & Johnson subsidiary Auris Health decided to make a switch before the close of fact discovery in a patent infringement suit brought by Intuitive Surgical involving robotic-assisted surgery technology; since becoming involved, the plaintiff has dropped three of the eight patents it originally asserted. Working with them on this is Tamir Packin, who is also heavily engaged in the firm’s representation of Cisco Systems; he and Jonas R McDavit – together with San Francisco-based Peter Magic – recently earned an important trial win invalidating $400 million in claims brought against the tech conglomerate by software company Egenera. An “excellent trial lawyer and brief writer”, McDavit is “one of the best litigators at one of the best firms”. Further firepower comes from Alan S Kellman and Karim Z Oussayef, who also have a lot on. Kellman has acted for Sound View Innovations in infringement litigation against multiple parties relating to multimedia streaming architecture, real-time data analytics and distributed computing technologies; while Oussayef, alongside John Desmarais, is representing IBM in asserting the infringement of 12 patents against online real estate website Zillow.

Fay Kaplun & Marcin LLP

Covering all bases in intellectual property, Fay Kaplun & Marcin provides joined-up counsel on patents, brands, copyright law and trade secrets, making those with diverse portfolios feel safe and protected. Maintaining a strong presence in all innovative industry sectors, the team conducts error-free prosecution while dispensing insightful guidance on strategic matters including IP transactions and PTAB proceedings. Spearheading the practice is Oleg Kaplun, a precision draftsman and prosecutor, and a trusted adviser for high-technology companies.

Fenwick & West LLP

Few firms have as mature an understanding of the technology world as Fenwick & West. By the side of cutting-edge companies at every stage of their innovation and business journey, the Silicon Valley native understands the potency of intellectual property as a commercial tool and how to harness it for maximum gain. This is a gift of Daniel Brownstone, a long-time member who acts as primary patent counsel to a ride-sharing service and an investment bank – both famous names with valuable IP holdings. Turning to litigation, Fenwick & West has come on in leaps and bounds in New York in recent years, as Jeffrey Oelke, Kevin McGann, James Trainor and Adam Gahtan – who joined as a redoubtable strike force in 2018 – quickly settled into their groove. Staying up on his grind, Oelke has been putting in the shifts for a leading global healthcare concern and a prestigious pharmaceutical company, showcasing his persuasiveness in trial and post-grant settings in the process. Sources appreciate his “open and honest dialogue, trustworthy legal assessments and willingness to go the extra mile and add value”. McGann and Trainor have also seen plenty of life sciences action, handling multiple matters for UCB and Lohmann Therapie-Systeme; in one case, they obtained a Federal Circuit-affirmed verdict of infringement under the doctrine of equivalents, having replaced prior counsel two years into the litigation and just four months before trial. Gahtan was also central to this result, as Fenwick’s appellate mastermind. Although life sciences work has been the dominant feature of their practices of late, none of these lawyers can be pigeonholed – which is a measure of the transferability of their refined trial skills.

Fish & Richardson

Fish & Richardson sets the coordinates for success in must-win patent litigation and engages hyperdrive to achieve it. In every venue, its lawyers make sound strategic plays and, when the time comes to stand up and present in court, they hit all the right notes. New York managing principal Michael Autuoro is great at mobilising colleagues and resources in the optimum configurations to get difficult jobs done. An experienced trial lawyer in his own right, he is also happy to play support roles when needed and took his cue from Edmond Bannon in a recent infringement matter for Floodbreak, which designs and manufactures flood mitigation systems that NYC Transit has purchased to prevent the subway system from being inundated in the event of a storm. Bannon is praised for his ability to “mount successful defences, work with third-party technical experts and help clients understand and prepare for depositions”. He is also credited for his abilities in the ITC, where he recently secured a business-critical win as lead counsel for respondent Momentive UV Coatings in a four-patent case against DSM Desotech and its parent involving patents on optical fibre coatings and coated optical fibres – one in which DSM sought an exclusion order against Momentive’s largest-selling coating. The ITC found all asserted claims of the patents in suit invalid or not infringed – a decision that the Federal Circuit subsequently upheld. Michael Zoppo is another adept litigator, but also leans into the prosecution and portfolio practice – which, from a New York standpoint, is another strong one. Tony Zhang and Jack Brennan each have PhDs – Zhang in chemistry and Brennan in genetics – and produce superior results for their life sciences followers. One notable client of Zhang’s is Reflection Biotechnologies, a patient-founded company with a focus on rare genetic diseases; his prosecution efforts have helped to attract major pharmaceutical companies to the licensing and collaboration deal table. Samuel Borodach repeats Zhang and Brennan’s success in the electronic, software and mechanical technologies areas and is a vital contributor to Fish’s exceptional post-grant offering.

Fox Rothschild LLP 

In the words of senior in-house folks: “The patent prosecution team at Fox Rothschild is first rate.” The firm has a great mix of technical talent – PhDs and engineers with law degrees – complemented by lawyers with both contentious and non-contentious and litigation experience. Led by Deborah Somerville in the New York office, the team “understands clients’ needs to a tee”. Immersing herself in the business side of things, Somerville “makes sure your intellectual property supports your commercial goals and fulfils her partnering role with the utmost professionalism, dedication and comradery. She’s first rate and a great asset to have on side”. She is by no means the only eminent life sciences patent attorney on deck: local managing partner and molecular pharmacology PhD Janet MacLeod, chemistry PhD Christopher Glynn and patent group leader Dianna El Hioum are also great options in this space. MacLeod undertakes prosecution and portfolio management for Lytix Biopharma and is a critical component of teams supporting academic institutions. Glynn regularly collaborates with Somerville – for example, in handling extensive due diligence tasks on behalf of Healthcare Royalty Partners. El Hioum supervises prep and pros relating to therapeutic antibodies – including FDA-approved therapeutics – for various cancer treatments for a leading biotechnology company.

Gibson Dunn & Crutcher LLP

Bet-the-company patent litigation is meat and drink to Gibson Dunn. Its lawyers shoulder the heaviest burdens for innovators in the media, technology, software and life sciences sectors, astutely leveraging the firm’s resources to advance creative, decisive strategies that get right to the heart of the dispositive issues in a case. Just seeing the name of Josh Krevitt, Daniel Thomasch or any number of their colleagues at the top of a brief is enough to take the wind out of opposing parties’ sails. Krevitt is a solid-gold lawyer whose feats in and out of court give him an aura of invincibility. He has undertaken extensive work on behalf of AT&T recently, scoring many quick successes against NPEs through aggressive motion practice and the development of ironclad defences. With him on a number of these matters, Benjamin Hershkowitz and Brian Rosenthal are similarly specced as unflappable trial advocates. Notable recent New York-led activities on the life sciences side include a significant victory for Novartis in which all challenges to a patent covering its blockbuster multiple sclerosis drug Gilenya were rejected. In this one, Jane Love and Robert Trenchard stayed the course through an inter partes review (2018), a preliminary injunction proceeding (2019) and a four-day bench trial (2020), and emerged victorious. Love is a registered patent attorney who demonstrates strategic brilliance in her handling of district court litigation (in which she serves as first chair) and co-pending PTAB proceedings. She and Trenchard form a dynamic pairing with an enviable hit rate.

Goodwin Procter LLP

Goodwin Procter makes light work of complex patent litigation in both the life sciences and high-technology domains, and New York is home to linchpins of both specialised practices. The firm is one of the most prolific players in Hatch-Waxman actions and an emerging leader in the field of biosimilars – see its Big Molecule Watch blog for all the latest on that front – and has a compelling trio of lawyers in Elizabeth Holland, Robert Cerwinski and Alexandra Valenti. Holland is an influential industry figure who has spent decades duking it out for pharmaceutical originators and generics. In one of her most significant ongoing cases, she is representing Novartis as complainant in an ITC action against Regeneron seeking an exclusion order against Regeneron’s newly launched Eylea pre-filled syringe product. Cerwinski is “someone you’re always happy to have on your side. He does a superb job as a team leader and gives clear strategic advice, helping clients to cut through the patent thicket”. With “outstanding IP knowledge”, he is “a sharp, creative, communicative lawyer who can be wholeheartedly recommended”. He is acting for Dr Reddy’s Laboratories in proceedings concerning its generic equivalent to Suboxone alongside Valenti and colleagues in Boston. Growing in stature and supremely confident in her trial skills, Valenti isn’t afraid of litigating outside her pharmaceutical stronghold and makes a significant contribution to the non-life sciences practice, which is headlined by Mark Abate and Calvin Wingfield. Both garner effusive client feedback: “Mark is a highly intelligent, professional and client-oriented litigation counsel. He has a deep appreciation of our patents – their development and how they improve the features and functionality of the products that embody them – along with the internal genesis of our innovations and the needs they were intended to address. He also has a deep understanding of how our products are perceived in the marketplace and therefore how to strengthen our defences. Mark collaborates well with in-house IP counsel, engineers and senior management, and is sensitive to the need for accurate litigation budget planning. All this applies equally to Calvin, who is excellent at explaining the complex aspects of patent litigation to those tasked with gathering and giving context to evidence required for presentation at trial. He meticulously tracks the evidentiary requirements to ensure they are met, and his all-round thoroughness and thoughtfulness are heartening.” They performed admirably for Pass & Seymour in a long-running dispute with Leviton Manufacturing, its core competitor in the ground-fault circuit interrupters market, emerging with a rare jury verdict of patent invalidation due to obviousness in a declaratory judgment action.

Greenberg Traurig LLP

Greenberg Traurig’s commerciality, energy, agility and service mindedness are put on full display by the New York IP team. Much credit for this is owed to Scott Bornstein, who recently took on the role of co-managing shareholder of the local office, which he fulfils while also co-leading the global IP and technology and patent litigation groups and serving on the executive committee. A wonderfully dynamic leader for the firm, he also puts in serious work as a litigator and trial lawyer: he recently represented Teva in a Paragraph IV challenge; and Kretek International, Dryft Sciences and others in an ITC and multi-district court litigation against Swedish Match and others involving tobacco-less nicotine pouch products. For Teva, he has linked up with smart life sciences and high-technology litigation strategist Richard Pettus and Jonathan Ball, an organic chemistry PhD who contributes vitally to the firm’s prosecution, portfolio management, licensing, post-grant and litigation practices. Holding it down in conflicts over computer, financial, medical device and communications technologies, meanwhile, is Joshua Raskin, who receives outstanding reviews: “From a customer service standpoint, Josh is incredible; he is also the sort of lawyer who you want to present to boards on litigation strategy. An excellent decision maker and writer, he consistently outworks and outthinks counterparties to lead his clients to sweeping victories.” He was recently hired by JPMorgan to defend against an inventor’s allegations of patent infringement and swiftly had the case dismissed. For this, he partnered with Rose Cordero Prey who garners equally enthusiastic praise: “Rose is organised, quick, responsive, diligent and a logical thinker who is brilliant at juggling all aspects of a litigation, while never losing sight of the big picture. She has such a robust patent skillset that she can quickly adapt to new cases, technologies and clients.” Raskin also forms a highly productive connection with Allan Kassenoff, with whom she has been defending Deezer in a patent infringement suit in which the court found all asserted patent claims invalid under Section 101. Kassenoff has tried multiple cases to verdict and maintains a vibrant practice spanning diverse industry sectors.

Haley Guiliano LLP

Technical dexterity and strategic assuredness are the hallmarks of Haley Guiliano’s offering. Focused on commercially consequential patent matters, the ensemble neatly aligns its approach and service with the business needs of clients, which enhances the value of its work product and its efficiency. For biotechnology and pharmaceutical players, James Haley and Karen Mangasarian are rock stars when it comes to global prosecution, portfolio management and IP planning. Haley takes advantage of his career-long exposure to complex litigation to chart risk-free paths forward and set patent rights in stone. Mangasarian has an affinity for landscape analysis and is a savvy transactional lawyer who ensures that clients can capitalise fully on commercial IP opportunities. Managing partner Joseph Guiliano provides the same high-impact service to high-technology companies. Like Haley, he has well-developed mentoring and leadership skills, meaning that those around him are highly motivated to achieve their best.

Haug Partners LLP 

Haug Partners may have made its name as an agile, business-focused contentious force, but today it is increasingly seen as a well-rounded boutique with a deft counselling touch and cultivated prosecution and transactions capabilities. The main headlines are still written by the group’s redoubtable trial lawyers, who include Edgar H Haug, Porter F Fleming and Brian V Slater. Haug is distinguished by his first-chair seasoning, appellate expertise and international experience; Fleming by his tirelessness and tenacity; and Slater by his life sciences industry knowledge and versatile patent procurement, licensing and enforcement skillset.

Hughes Hubbard & Reed LLP

Hughes Hubbard has etched its name into the patent history books on a number of occasions: cases that bear its stamp include KSR International v Teleflex – a Supreme Court decision that set a precedent on the interpretation of the non-obvious subject matter condition for patentability under Section 103; and TC Heartland v Kraft Food Group Brands, which established a new standard for interpretation of the rules on patent venue. This reflects the firm’s willingness and ability to push boundaries, which is something that IP and technology group chair – and adjunct professor of law at Cornell Law School – James Dabney has done throughout his storied career. He and Patrice Jean continue to make a splash in weighty cases: for example, they recently successfully represented Cipla in resolving patent and antitrust litigation against rival Amgen, enabling their client to import and sell a generic version of prescription drug Sensipar. Jean chairs the life sciences group and is a litigator and counsellor par excellence, with a PhD in molecular biology.

Hunton Andrews Kurth LLP

Renaissance man Gary Abelev embodies Hunton Andrews Kurth’s well-roundedness in patents in his own practice, which encompasses litigation, due diligence studies, portfolio management and development, patent procurement and licensing. At ease with myriad technologies, he has an incredibly broad sphere of operations – one reason why several prestigious universities select him as their preferred patent counsel. Showcasing the firm’s suitability for high-stakes patent litigation, on the other hand, is John Flock, “one of the market’s most strategic and pragmatic litigators” and “a top choice to lead complex global cases”. Well known for his work on behalf of Sony, he has continued to represent the company recently, including in an investigation at the ITC. Indeed, Hunton Andrews Kurth should be noted for the robustness of its ITC practice: it ranks high among the most active and best-performing firms in the forum.

Jones Day

Pioneers in the life sciences derive major benefits from partnering with Jones Day: it fields elite-level strategic counsellors and litigators, and offers a global support package. For complex prosecution, insightful opinions and flawless representation in post-grant proceedings and touch-and-go transactional negotiations, Adriane Antler is the essential choice. An accomplished Hatch-Waxman litigator who has enforced patents protecting many blockbuster drugs, John Normile is the person to call for hotly contentious matters.

King & Spalding LLP

King & Spalding enjoys an outstanding reputation in the pharmaceutical and biotechnology fields. Key reasons for this include the quality, experience and track record of its litigators; but these are by no means the only reasons. The firm also runs a mature, industry-focused prosecution, counselling, diligence and licensing practice, and integrates its IP offering with highly rated practices in FDA regulatory law, product liability and government investigations, among others – all of which makes for a sophisticated wraparound service. Returning to those trial lawyers, Gerald Flattmann, Evan Diamond and Vanessa Yen form an imposing line-up fit to tackle any complex case. The close-knit team has had a lot going on recently: by way of example, it represented Galderma in a trial regarding Sun Pharmaceuticals’ attempt to design around the formulation patents covering Oracea, Galderma’s rosacea treatment, which has chalked up $3 billion in sales since its launch. Sun’s product was found to infringe Galderma’s patents and its invalidity claims were rejected; Sun also withdrew its appeal to the Federal Circuit, keeping the trial win in place and resolving the last pending challenge to the Orange Book listed patents protecting Oracea. As global chair of life sciences patent litigation, Flattmann brings strong leadership to the group. High-technology concerns aren’t left feeling short-changed by King & Spalding’s New York contingent: Allison Altersohn is there with them both in litigation and as a portfolio and licensing strategist. She recently achieved an impressive walkaway win for Delta Airlines, against which Sound View – which has been terrifically successful in monetising its patent portfolios through litigation against other companies – asserted four patents directed to high-performing computing functionality.

Kirkland & Ellis LLP

Kirkland & Ellis is ever-ready for trial – a state that helps it to develop clear, compelling themes from the moment a case is filed, create threat value to drive favourable settlements and assert its will in the courtroom. The firm’s New York lawyers have kept the results tracker busy of late: Gregory Arovas, Todd Friedman and Robert Appleby, for example, scored a major victory for Intel and its customers Acer, AsusTek Computer, Lenovo and Micro-Star International at the ITC with a May 2020 final determination of no violation in an action filed by Tela Innovations, which sought to prevent the import and sale of Intel’s most cutting-edge microchips, as well as the customer-manufactured devices containing them. This result will be beneficial in the context of the district court litigation between the two parties on the same patents running in parallel. Arovas, Appleby and Jeanne Heffernan carried the day in another notable ITC matter which cannot be disclosed, but which pitted a global technology leader against an NPE. Arovas and Patricia Carson swiftly saw off a challenge against Samsung Electronics in a suit filed in the Eastern District of Texas by Greenthread alleging infringement of patents relating to semiconductor memory chips and image sensors. In terms of ongoing action, Joseph Loy has teamed up with illustrious colleagues Paul Brinkman in DC and Nicola Dagg in London to represent AutoStore Technology in multi-jurisdictional patent litigation against Ocado Group and its subsidiaries concerning patents relating to automated storage and retrieval systems. The takeaways from all this are that Kirkland’s lawyers are trusted by cutting-edge industry leaders to handle the biggest cases playing out across multiple US forums and internationally – and they consistently deliver satisfying outcomes. More than just a side hustle, the firm also handles big-ticket transactions with aplomb, and David MacDonald is the fulcrum around which this practice turns in New York. On the life sciences side, recent highlights include representing Boehringer Ingelheim in negotiations to restructure its diabetes alliance with Eli Lilly and Company; and acting for Samsung Bioepis in licensing negotiations regarding its biologics. On the high-technology front, he has served as outside counsel to the Open Innovation Network in its role as a patent non-aggression community that supports freedom of action in Linux as a key element of open source software.

Latham & Watkins LLP

Latham & Watkins has been making power plays in the life sciences patent litigation arena lately: the recruitment of gold-ranked Adam Perlman from prestigious firm Williams & Connolly was a major move at the start of 2020, and was followed up in the summer with the addition of Arlene Chow from Hogan Lovells. Chow is a seasoned representative of branded pharmaceutical companies in all kinds of drug litigation. Passionate about the science, she has the essential gift of distilling the technical complexity out of her cases to present clear and resonant narratives in court. She joins fellow New Yorker Daniel Brown, an expert in FDA and regulatory law with a blended trial and transactional skillset. Their counterpart on the high-technology side is Clement Naples, who brings the heat in semiconductor, communications, automotive technology and other disputes.

Leason Ellis LLP

Only four firms out of a total of 48 listed in the IAM Patent 1000 New York section are recommended on each of the prosecution, litigation and transactions tables – and Leason Ellis is one of them. Its outstanding versatility is further reflected in the individual rankings: it has six attorneys honoured for prosecution along with three in litigation and two in transactions. This gives it the deepest prosecution bench in the city, which highlights just how strong its patent fundamentals are. Commenting on this, clients acknowledge: “It has a well-balanced staff of lawyers with wide-ranging technical expertise and an excellent comprehension of some of the more abstruse areas of technology. The group is highly organised, uses up-to-date practice management techniques and is well connected overseas with top-rated foreign counsel.” The most enthusiastically endorsed practitioners include Elizabeth Barnhard, who chairs the pharmaceutical and biotechnology practice: “Working with Elizabeth leads to added value and business growth. She steers patent matters in assured fashion and secures allowances with the minimum level of exchange with examiners, which is key to saving costs. Her strategies are productive and effective, and she gives clients full confidence in the achievement of their commercial objectives.” She and fellow life sciences maven Susie Cheng are “thorough professionals who always keep your, not their, best interests in mind. They are reliable and fast communicators who complete assignments swiftly and provide great recommendations leading to successful registrations”. A fluent Cantonese and Mandarin speaker, Cheng takes charge of a dedicated China practice group that gives the firm a real USP. Physician Michael Davitz also levels up the practice, given his extensive research background, global prosecution expertise, transactional know-how and disputes experience. Technology innovators looking to procure valuable patents have similarly high-spec partnering options in Matthew Kaufman and founders David Leason and Edward Ellis. Kaufman applies his enforcement learnings to great effect in prosecution, securing his followers cast-iron rights that can withstand any challenges. Managing partner Leason is a one-stop shop for strategic IP counsel, given his deep familiarity with all IP categories; he brings innovative ideas to the table that spark ‘lightbulb moments’ for clients. Chair of the patent group Ellis also thinks on a higher strategic plane, but is a down-to-earth lawyer who listens to clients so that he can better understand what they need and tailor his service accordingly. Yuval Marcus, Robert Isackson and Melvin Garner form the backbone of the litigation practice, with Marcus serving as chair. Coming in for special praise, Isackson “applies a practical, common-sense approach and has the ability to explain complex matters simply, yet precisely. Unlike many lawyers, he doesn’t equivocate, but provides direct and useful advice. He is insightful about how intellectual property can be employed to drive value for a company”. He and Garner give Leason Ellis a great deal of trial seasoning.

Mayer Brown

Mayer Brown provides fulsome support to pharmaceutical originators, biotechnology companies and medical device innovators. Well equipped to litigate high-profile Hatch Waxman and Biologics Price Competition and Innovation Act cases at the trial and appellate level and before the PTAB, the firm is also in hot demand for commercial deal work, in recognition of which it secures its first inclusion on the IAM Patent 1000 New York transactions table for 2021. Taking the lead on all fronts is Lisa Ferri, who co-chairs the global IP and life sciences groups. She is currently representing patent holder Gilead Sciences and its licensee of the patents in suit, Astellas, in a Hatch-Waxman action in the District of Delaware against 11 defendants’ groups involving Gilead’s successful Lexiscan product. An especially notable transactional highlight, meanwhile, saw her link up with Brian Nolan plus Dusseldorf-based patent partner Christoph Crützen to advise Bristol-Myers Squibb on its $74 billion acquisition of Celgene. Nolan is one of Ferri’s frequent collaborators, as is Richard McCormick; the three of them form a dynamic and agile team whenever a case or matter demands added firepower.

Milbank LLP

A SWAT team for high-stakes litigation, Milbank has a proven ability to win when everything’s on the line. The practice in New York is anchored by Christopher Gaspar and Errol Taylor, two dyed-in-the-wool trial lawyers and strategic visionaries who provide exceptional leadership from start to finish of a matter and who can take over tough cases and turn them around. Gaspar keeps a lot of balls in the air without dropping them or giving clients anything less than a stellar service. He is currently representing MRSI Systems in proceedings brought by Palomar Technologies relating to the use of a machine in the manufacture of semiconductor products; defending Fujitsu Network Communications in a complaint filed in the Eastern District of Texas by Capella Photonics, which he has beaten on the same technology in a previous action; and acting for healthcare-focused private equity company Auven Therapeutics in the defence of claims made by The Curators of the University of Missouri concerning inventions treating ocular conditions. Meanwhile, Taylor is fighting the corner of Tris Pharma in multiple suits.

Norton Rose Fulbright

Norton Rose Fulbright offers a comprehensive suite of patent services, but is recognised in New York for its prosecution proficiency. Gerard Messina and his colleagues get to grips with large portfolios with the greatest of ease, while applying finely honed drafting skills to the procurement of fresh patent assets. One of the ensemble’s largest clients is Robert Bosch, which assigned it back in 2016 with responsibility for more than 2,000 pending US applications. Some of the technologies involved relate to autonomous driving, which plays into one of Messina’s sector strengths – automotive; he also acts for Knorr-Bremse, a global leader in braking systems for road and rail vehicles.

O’Melveny & Myers LLP

There’s always a buzz around O’Melveny’s New York patent group, which punches well above its weight in numbers to take on the most complex and demanding Hatch-Waxman and Biologics Price Competition and Innovation Act litigations – and win. Lisa Pensabene brings tremendous energy to the practice and comes in for vocal praise from the clients that know her best: “Lisa is an excellent attorney and strategic thinker who can go toe to toe with anyone on the technical side; she takes apart opposing experts on cross-examination with ease. She has this unique ability to develop rapport and trust with witnesses, so they have the utmost confidence when testifying – a skill which also serves her well before many judges.” She litigates extensively for Onyx Therapeutics, an Amgen company, and recently earned an important trial win in litigation involving cancer drug Kyprolis, in which the District of Delaware chief judge ruled that claims in all three asserted patents were valid and infringed by Cipla. With her on this was Hassen Sayeed, who also attracts glowing reviews: “Hassen is thorough and responsive, and achieves clients’ goals even under immense time pressure. His work product is consistently excellent and he’s brilliant at spotting tangential issues that ultimately are of importance.”

Paul Hastings LLP

For pharmaceutical originators and biotechnology companies facing business-critical contentious threats, Paul Hastings is a guiding light. It deploys hard-hitting, exceptionally rigorous trial lawyers to the frontlines while taking full advantage of its rich technical resources – the life sciences IP group comprises 40 lawyers and advisers with relevant technical degrees, including 10 PhDs – and international office network. The indomitable Bruce Wexler paces the team in New York and serves as global co-chair of the IP practice. The value of his leadership cannot be overstated in the context of big-ticket litigation, which is why he is highly prized by some of the largest drug companies in the world – Johnson & Johnson among them. He and Preston Ratliff have represented Actelion Pharmaceuticals, a Johnson & Johnson company, in multiple patent infringement suits – some of which are ongoing, but others which have closed with what effectively amounted to walkaway wins, the defendants having entered consent judgments and agreed to respect the asserted patent’s full term. Ratliff II, who captains the litigation practice in New York, has flourished at Paul Hastings, being blessed with the temperament, talent and trial skill necessary to bear heavy loads for the firm’s clients. He and global IP group vice chair Eric Dittmann are cut from the same cloth and are both present and future stars of US patent litigation practice. For Dittmann, defending key Orange Book patents covering blockbuster endocrinology drugs Invokana and Invokamet on behalf of Mitsubishi Tanabe Pharma Corporation (MTPC) has been a major recent focus; this involved conducting a Hatch-Waxman trial over Zoom which, at the time, was only the second such case to have been tried virtually. Other key contributors to this soaring group include Isaac Ashkenazi, who supported Dittmann in his MTPC work and has led other matters alongside Wexler; and Chad Peterman, who litigates with confidence and poise in the life sciences and high-technology realms. Well-equipped for high-level transactions, too, Paul Hastings has an experienced M&A, emerging growth company and IP licensing lawyer in New York in Samuel Waxman.

Paul Weiss Rifkind Wharton & Garrison LLP

Paul Weiss is a compelling choice for the most newsworthy patent disputes, thanks to the obsidian-sharp trial, appellate and post-grant skills of its lawyers, its strategic innovativeness and its outstanding track record. All of this is on full display in its cutting-edge representation of Amgen in a host of patent litigations and related PTAB proceedings concerning competitor applications to market biosimilars under the Biologics Price Competition and Innovation Act. Spearheading this is Nicholas Groombridge, who is simply one of the best courtroom lawyers in the country. His approach is a collaborative one that supports the seamlessness with which Paul Weiss configures optimised litigation teams. He regularly connects with DC-based post-grant supremo Steve Baughman and New York colleagues Eric Alan Stone, Catherine Nyarady and Jennifer Wu. Stone guides clients through unique challenges with an unerring compass and has put in resonant performances for Genetech; Nyarady has been integral to Paul Weiss’s representation of market leaders Edward Lifesciences and Nichia Corporation in multi-jurisdictional battles; and Wu is an engine of the firm’s biologics work.

Pearl Cohen Zedek Latzer Baratz

International outfit Pearl Cohen earns rave reviews: “Its highly professional, dedicated, smart and practical lawyers navigate complex areas of intellectual property in a masterful way. Their attention to detail is impeccable and they are immediately responsive, too.” The focal point for praise is managing partner and technology, medical and telecoms group chair Zeev Pearl, a “rare combination of businessman, patent attorney and scientist”. “Zeev understands technical issues perfectly, but his starting point is always ascertaining the commercial objectives of his clients. Incredibly thorough and articulate – and responsive 24/7 – he is a trusted adviser and true partner who delivers the highest standard of work.” To give but a sampling of his activities, he undertakes prosecution assignments for Morgan Stanley; marshals a cross-border team that takes care of Telit Communications’ large global portfolio; and secures vital registrations at the USPTO for Volkswagen Group. His counterpart in the pharmaceutical area is global life sciences group chair Mark Cohen, who represents the University of Pennsylvania and the University of California, Los Angeles, as well as companies such as Humanigen, to which he provides sweeping strategic patent support. As a leading commercial IP lawyer, Cohen also runs a busy deal practice alongside his prosecution work. Guy Yonay anchors the litigation division. Having been put to the test in a diverse array of IP (not just patent) cases, as well as unfair competition and other disputes, he has sharpened his advocacy skills to a fine point.

Perkins Coie LLP

Perkins Coie litigates patent cases constantly, putting in winning performances in district courts, as well as at the ITC, the PTAB and the Federal Circuit. The firm has elite patent litigators stationed in economic hubs all around the country, including New York, where William McCabe and Gene Lee – two lawyers with vast experience representing a worldwide client base in US and international high-technology litigations – are based. Together – and with the support of local colleagues, as well as associates in Texas, Colorado and California – they act for Finnish Android-based smartphone manufacturer HMD Global, known as the home of Nokia phones, defending its technology in multiple cases.

Proskauer Rose LLP

A one-stop shop for life sciences and technology innovators, Proskauer Rose capitalises on the rich scientific expertise of its staff for prosecution, calls and executes the right plays in complex litigation, and gets signatures on the dotted lines of major transactions. It can carry out instructions globally, too, with members of its US, European and Asian bureaux regularly interacting with patent offices all over the world to secure consistent cross-border protection for clients. Flying the firm’s flag in New York are litigators James Shalek and Baldassare Vinti; and managing partner and head of life sciences Daryn Grossman, a shrewd transactional lawyer. Shalek builds longstanding relationships of trust with patrons and has taken the lead on contentious matters for British Telecommunications, Church & Dwight and many others. He’s great at breaking down the science and weaving stories around it that appeal to juries and triers of fact. Vinti, with whom he regularly works, brings great energy and commerciality to his representations and excels throughout all phases of litigation, including trial. Grossman cements the deals that are most critical to the success of her clients’ global expansion strategies. In one recent highlight, she advised Grifols on the closing of its $1.9 billion alliance with Shanhai RAAS Blood Products, China’s leading blood plasma company; among other notable points, this was the first-ever stock-for-stock deal involving an overseas public company and a non-state controlled Chinese public company. Grossman is at the top of her game right now.

Quinn Emanuel Urquhart & Sullivan LLP

Quinn Emanuel has made intellectual property a central pillar of its full-bodied commercial practice and enjoys prominent status as a market leader for patent litigation, both in the United States and globally. When there’s much to gain and much to lose, technology leaders take heart from the firm’s measured aggression, tactical nous, win rate and bench depth. On this latter point, Quinn Emanuel has a large number of representatives in the IAM Patent 1000’s New York coverage. They include national IP litigation group co-chair Edward DeFranco; Peter Armenio, a life sciences doyen whose work for the likes of Allergan ensures years of additional patent protection and revenue generation; fellow pharmaceutical stars Sandra Bresnick, Dominic Cerrito and Colleen Tracy James; biochemistry PhD Angus Chen; litigation, standards and licensing ace Thomas Pease; computer hardware and software specialist Richard Erwine; and Raymond Nimrod, who plays a strong hand in life sciences disputes – he is currently acting as lead counsel for Janssen Pharmaceuticals in Hatch-Waxman litigation relating to its blockbuster diabetes drugs Invokana and Invokamet, which have combined sales of over $1 billion – and high-technology cases. Trial skill, experience and a will to win are what these lawyers all have in common. The other name to note is Kathleen Sullivan, one of the foremost appellate advocates in the country.

Robins Kaplan LLP

Robins Kaplan acquits itself with distinction enforcing patents for monetisation purposes and defending clients’ innovations; operating on both sides of the ‘v’ affords it rare insight into the tactics and mindset of its opponents, which it turns to its advantage time and again. Bryan Vogel founded the New York office over a decade ago and has been a powerful engine of the firm’s success in US patent litigation (across all forums), arbitration and cross-border litigation. He puts in work at the ITC and captains a dynamic Section 337 investigations practice. Elizabeth Gardner joined in 2018 and has since ramped up the life sciences division considerably. She knows when to push and when to hold back, and is guided by an appreciation of the commercial big picture.

Ropes & Gray LLP

Active in the lateral recruitment market, Ropes & Gray has transformed its New York IP group in recent years, giving it added impetus in the life sciences litigation and patent transactions domains in which the firm is so strong at the national and international level. The most recent addition was Violetta Kokolus, who joined in May 2019. The former Dechert partner is in her element negotiating IP and data-intensive licensing agreements and resolving complex IP issues arising in the course of major M&A transactions. The previous year saw the arrival of Filko Prugo and Charlotte Jacobsen, who have seamlessly carried on doing what they do best: litigating complex pharmaceutical, biologics and other cases. Together, they are representing ArcherDX in proceedings filed by competitor Natera relating to amplifying and sequencing cell-free DNA; the suit concerns almost every product in ArcherDX’s portfolio, making it of critical business importance. Prugo and Jacobsen pull all the right levers in district courts, the PTAB and at the Federal Circuit, and afford complete coverage for their clients. An absolute rock for the firm throughout a period of change, Steven Pepe is a seasoned lead and co-counsel with a focus on semiconductors, computers, communications and consumer products. Not just an excellent presenter, he’s also brilliant at coordinating large cases across multiple forums.

Shearman & Sterling LLP 

The IP specialists at Shearman & Sterling never lose sight of the commercial imperative when litigating patent cases; as a result of this laser focus, their strategies are better targeted and more carefully calibrated, and their outcomes – whether trial wins or settlements – are custom fitted to client needs. Head of intellectual property Mark Hannemann and fellow New Yorker Thomas R Makin are the firm’s driving forces on the East Coast and both garner warm praise from the market. “Mark is smart and efficient, and his advice and arguments are always very much to the point. He’s great on the technology and a quick study in terms of how clients’ products work and what makes their business tick.” “Someone you can trust”, Makin “builds persuasive stories around his theories. He is thoroughly up to date on relevant industry and patent law developments, and gives sage advice that helps direct smarter future decision making”. Their recent highlights include a significant win for Nichia and OSRAM against Lighting Science Group in the ITC: the administrative law judge granted summary determination of no infringement on each of Nichia’s and OSRAM’s products and lack of technical domestic industry on half of the patent claims, and subsequently issued an initial determination finding the remaining claims – some of which were deemed invalid – to be not infringed. Shearman & Sterling is, of course, a premier corporate law firm and as such runs a high-performance IP and technology transactions practice. Integral to this, Jordan Altman is a deal driver with a broad IP skillset, thanks to a background prosecuting and litigating patents. He undertook intensive IP work on behalf of Raytheon Technologies with respect to its merger of equals with United Technologies.

Sidley Austin LLP

“Sidley Austin has incredible depth as a full-service legal provider and as partner for patent litigation.” The prestigious firm’s New York team is stacked full of high-level operatives, including Jim Badke and Ching-Lee Fukuda, who are cited by appreciative patrons for their special attributes. “Jim is fully engaged in his matters and provides the very highest level of service. His cases are crafted with attention to detail and his teams work with amazing efficiency, engaging in healthy and smart debate on substantive issues without egos ever getting in the way. He’s incredibly practical and a tenacious fighter who never quits.” Fukuda is a “wonderful team player with superb legal acumen who can handle the most complex of cases”. Together they netted a significant victory for BioTelemetry (CardioNet) when the Federal Circuit, reversing a district court decision, found BioTelemetry’s patent to be eligible under Section 101; this is a rare Federal Circuit win for a patent owner on Section 101 and is significant in providing guidance on the importance of reciting the advantages of an invention in the specification – particularly in the medical technology and diagnostics space. They form a close-knit and formidable unit with Sona De; all three have been representing Bayer Healthcare in a Federal Circuit appeal which followed a major high-profile damages award secured against Baxalta in US litigation as a component of a global legal battle between the two parties concerning the market for haemophilia treatments. Worthy of special mention, too, is Sidley’s technology and IP transactions practice, which is co-led globally by Jennifer Coplan. Breaking new ground in the insurance sector, Coplan and co recently assisted a major life insurance company on the negotiation of a technology services transaction for the development and provision of an artificial intelligence (AI) driven accelerated underwriting technology solution.

Skadden Arps Slate Meagher & Flom LLP

High-end patent litigation and transactions are the metier of Skadden, which is a go-to when creative patent strategies are needed. New York is the epicentre of its contentious and non-contentious practices, as the home of trial lawyers Anthony Sammi and Douglas Nemec and top deal brokers Jose Esteves, Resa Schlossberg and Stuart Levi. Head of IP litigation Sammi is advising Caterpillar in an ongoing patent and IP licensing dispute with a software services provider; representing pressure control equipment manufacturer FHE USA in two competitor infringement disputes; and acting for Juno USA in multiple infringement cases relating to ride sharing technology. Working alongside Sammi on all of these matters, Nemec has also represented Array Biopharma in a dispute with AstraZeneca, shooting down the latter’s attempt to dismiss a contract claim brought by Array, which alleged that AstraZeneca had failed to pay $200 million in royalties due under a previous deal in which it sub-licensed Array’s drug selumetinib to Merck. Recent transactional highlights for Esteves include advising Massachusetts Mutual Life Insurance Company on the $2.35 billion sale of its retirement plan business to Empower Retirement; and assisting ZeniMax Media with its high-profile $7.5 billion acquisition by Microsoft. Schlossberg’s mega-deals include DuPont de Nemours’ $45.4 billion merger of its nutrition and biosciences business with International Flavours and Fragrances Inc in a Reverse Morris Trust transaction. Levi – who co-heads the IP and technology group – remains a leading name in the transactions field, but has sharpened his focus on blockchain, privacy and cybersecurity matters.

Steptoe & Johnson LLP

The support package that Steptoe & Johnson provides to pharmaceutical and biotechnology companies is extremely well rounded. In immunology PhD Ying Li, the firm has a magnificent portfolio manager, counsellor and due diligence lawyer with superb technical credentials. “Ying is an outstanding strategist and someone you can trust with your most valuable portfolios. She is also a wonderful mentor and has built a strong team of associates.” The specifics of her recent work can’t be disclosed, but she gives rigorous support to top pharmaceutical manufacturers, innovators in the field of gene editing and rare diseases, and a biotechnology-focused venture capital company. Meanwhile, in John Molenda – another of the group’s PhDs – and Vishal Gupta, the firm has eminent litigators who join forces to provide a killer one-two punch. They have been litigating extensively for Apotex in cases involving its generic versions of Celgene’s blockbuster blood cancer drug Revlimid and Pfizer’s renal cancer drug Inlyta. They also continue to be engaged in Sanofi and Regeneron’s battle with Amgen over Praluent, and are now at the Federal Circuit following Amgen’s appeal of its remand trial win in August 2019, in which all asserted patent claims were invalidated.

Sullivan & Cromwell LLP

Sullivan & Cromwell’s litigators and transactional specialists live for cutting-edge, genre-defining, commercially significant IP and technology disputes and deals. Their work often takes them into uncharted patent waters, which they navigate with an unerring compass to bring clarity to issues and victory to clients. Among the very best that the market has to offer, trial lawyer Garrard Beeney is a model of civility, sophistication and excellence in the law. As part of his current workload, he is representing Columbia University in litigation against Symantec regarding inventions used to detect malware in computer systems; capitalising on his refined transactional skillset, he is also acting for Via Licensing in a dispute arising from a licensing agreement. With him on the former matter is Dustin Guzior, a rising star of the practice who makes his first appearance in the IAM Patent 1000 this year. They were recently joined by former Desmarais lawyer and experienced IP litigator Laurie Stempler, who took up the role of special counsel in March 2021. On the transactions side, Mehdi Ansari and John Evangelakos have been making waves brokering billion-dollar deals. Linking up with Palo Alto’s Nader Mousavi, Ansari represented DISH Network in its acquisition of the Boost pre-paid mobile business of Spring Corporation for $1.4 billion in cash; he also represented Novartis in its acquisition of The Medicines Company for an equity value of $9.7 billion. Evangelakos remains a reference for technology and financial services deals, and is a leading authority on cybersecurity.

Venable LLP

With its New York lawyers in the driving seat, Venable has been on a fine run of form in patent litigation of late. Much credit for this is owed to Dominick Conde, William Solander, Ha Kung Wong and Scott Reed, who form the nucleus of one of the best pharmaceutical and biotechnology groups around – as their caseload bears out. IP division co-chair Conde represents Allergan and is opposing a challenge to a patent relating to its Botox product; Solander has enjoyed great success in multiple post-grant reviews on behalf of Grünenthal and Abiogen Pharma to invalidate patents owned by Antecip Bioventures II relating to treatments for complex regional pain syndrome; Wong has been contributing in vital ways on the litigation front – for example, supporting Conde in his Allergan work – while also maintaining a strong focus on licensing and acquisitions; and Reed continues to bring leadership as co-chair of the IP litigation life sciences group. Props also go to Michael Sandonato, Frank Gasparo and Christopher Borello, who take centre stage when high-technology disputes need to be fought and won. Sandonato has been busy for long-time client Canon and is defending it in two NPE suits; Philips is his other main representation – he is serving as lead counsel for the company in a set of consolidated cases involving patents on graphical user interface, streaming and content protection technologies, many of which have been resolved favourably, but with one trial coming up. He co-chairs the IP litigation division with Gasparo, an adept, business-focused trial lawyer who makes all the right plays in district courts, the ITC, the PTAB and the Federal Circuit. Not easily pigeonholed, Borello performs adroitly in pharmaceutical and non-life sciences cases; capitalising on his patent counselling and portfolio development know-how, he addresses litigation issues holistically. An expert on biologics and small molecule pharmaceuticals with research experience on her CV, Alicia Russo is a highly proficient deal lawyer. She does great and many things for Gilead Sciences, and recently oversaw its $21 billion acquisition of Immunomedics.

Weil Gotshal & Manges LLP

Weil has an enduring reputation for excellence in high-exposure patent litigation between competitors, whose results transform fortunes and impact on entire industries. Elite lawyers in Silicon Valley, Houston, DC and New York help to sustain the firm’s legacy, Elizabeth Weiswasser and Anish Desai among them. Weiswasser is perfectly suited to her role as co-head of life sciences, given her strong technical background, decades on the frontlines of headline-writing cases, leadership and mentoring skill, and commitment. Desai is making a name for himself in district court litigation, post-grant proceedings and appeals, and frequently collaborates with colleagues such as Weiswasser and DC’s Brian Ferguson, with whom he has been representing GE Aviation in 36 inter partes review petitions challenging Pratt & Whitney patents. With a 26-lawyer specialised group spanning Silicon Valley and New York, Weil is also a dominant force when it comes to patent and technology transactions. Cutting-edge instructions are very much the order of the day for Michael Epstein, Jeffrey Osterman and Charan Sandhu, each of whom is highly recommended in the IAM Patent 1000 alongside just five other New York-based specialists from competing firms. Talisman of the practice Epstein continues to do amazing things for Campbell Soup Company, L’Oréal, Sanofi and others. Garnering special praise this year, Osterman has deep scientific knowledge and legal expertise that are unsurpassed in the profession. Working long hours seven days a week to deliver an outstanding-quality end product, “he makes the life of a general counsel much easier”. He is a trusted confidant to major pharmaceutical companies. Sandhu has racked up many billion-dollar deals and is the first choice of one of the world’s leading technology companies. Her efforts on the diversity front and her civic contributions also deserve applause.

White & Case LLP 

White & Case is in pole position to take on bet-the-company disputes with complex patent, antitrust, breach of contract and licensing componentry. The broad horizons of its top trial lawyers are immeasurably helpful in this regard. A-lister Dimitrios T Drivas, for example, brings to bear profound life sciences industry and technical knowledge along with a well-rounded contentious, counselling and transactional toolkit. Alison Hanstead – who also possesses heightened pharmaceutical powers – has a rare faculty for matters in which patent and competition issues intersect; so too does Raj Gandesha who has litigated a diverse array of IP, antitrust and commercial suits with equal dexterity throughout his career. Scott T Weingaertner’s versatility allows him to switch between major biosimilar and high-technology conflicts without batting an eyelid. Sophistication is also a hallmark of White & Case’s transactional practice. Adam Chernichaw – who was pivotal in launching the firm’s global technology transactions offering – is at the leading edge of business in the fintech space; Arlene Arin Hahn hails from a litigation background and has finely honed presentation skills that serve her well at the negotiating table; and global thinker Erin Hanson sees things through clients’ eyes.

Wilmer Cutler Pickering Hale and Dorr LLP

The high-calibre attorneys at WilmerHale have a rich comprehension of the life sciences, with many regularly putting in textbook-worthy performances at trial. Boston-based IP litigation co-chair Lisa Pirrozzolo immediately comes to mind; as do New York residents Robert Gunther, David Bassett and Christopher Noyes, who form a tailor-made strike force for prestigious clients. Gunther is at the vanguard of biosimilar patent litigation and is near-constantly on assignment for Genentech in such matters; this work alone has given him huge experience in PTAB proceedings, which he handles – and coordinates with litigation – with exceptional poise. Bassett has served as lead counsel at trial on many occasions and is a veteran of Hatch-Waxman and other life sciences suits. New to the IAM Patent 1000 for 2021, Christopher Noyes is “an absolute star who never misses his mark”: “Chris’s attention to detail is top notch; as is his appreciation of the real needs of his clients.”

Winston & Strawn LLP 

One of the country’s elite patent litigation firms, whichever way you cut it, Winston & Strawn has an NFL-sized squad of trial lawyers which takes on some of the highest-stakes representations and gets the job done in all forums. Increasing Winston’s visibility in New York is Krishnan Padmanabhan, a former semiconductor engineer for a major aerospace company with impressive technical fluency and commercial acumen – attributes he applies to great effect throughout all phases of complex litigation. He has turned heads with his litigation efforts in the communications and networking fields, and recently represented Cisco in seeking a declaratory judgment of non-infringement of a patent that Uniloc alleged was infringed; following Uniloc’s counterclaim, Padmanabhan and California-based David Enzminger obtained judgment on the pleadings that the claims were unpatentable under Section 101, which they then backed up at the Federal Circuit. Winston is also a destination for patent prosecution and counselling – a practice which Pejman Sharifi keeps humming.

Other recommended experts

Karen Bromberg provides staunch leadership to Cohen & Gresser’s IP and technology and privacy and data security practices; she is also an adept litigator and deal negotiator, with a strong business sense. Laura Brutman takes charge of Schiff Hardin’s prosecution practice. She has forged longstanding relationships with major players in diverse areas such as industrial manufacturing, computer technology and semiconductors, which trust in her technical abilities, strategic counsel and insightful opinions. Confident in his deep experience, extensive preparation and well-considered strategies, Joseph Calvaruso never flinches in the courtroom; he is one of Orrick’s crack IP litigators, while colleague Joshua Rosenkranz is a primed and polished appellate lawyer. Proficient across the IP spectrum and an all-round pharmaceutical litigator, patent filer, licensing lawyer and counsellor, Locke Lord IP chair Alan Clement sees the whole playing field for clients. Colleague Peter Fill has a similarly broad IP view: he undertakes extensive patent procurement and protection assignments for an innovative leader in 5G, networks and phones and a multinational energy sustainability and efficiency-focused technology company, earning him a spot in this year’s IAM Patent 1000 prosecution rankings. Ivor Elrifi excels in his role as chair of Cooley’s global patent counselling and prosecution group. His strategic advice is like gold dust for pharmaceutical and biotechnology companies, universities, research foundations and others on whose behalf he has sewn up many transformative deals and alliances. Adam Golden captains Hogan Lovells’s New York corporate practice, but earns his IAM Patent 1000 stripes courtesy of his specially developed IP transactions nous. Many notable deals in the pharmaceutical, biotechnology and medical device spaces bear his fingerprints. Christopher Harnett has built his career on his ability to prevail in tough patent infringement and other IP disputes. A blend of advocacy skill, technical know-how and business sensitivity makes the Maynaard Cooper shareholder a force to be reckoned with. An “aggressive litigator and tough negotiator”, David Hecht of Hecht Partners “has a brilliant legal mind and a passion for the law along with free-flowing writing skills”. “He gives personal attention to his clients and their cases, is extremely patient, excellent at communication and brilliant on strategy”. Philip Hirschhorn has over 30 years of litigation and trial experience and has seen combat in a great variety of technology areas and industries, notably including the life sciences. He is an astute legal problem solver who never takes his eyes off the business picture. Panitch Schwarze is his base of operations. Pryor Cashman partner Jeffrey Johnson understands the business of intellectual property and educates SMEs on the best strategies for protecting intangible assets and getting optimum return on their investment in them. An anchor member of Akin Gump’s sterling patent litigation group, Michael Kahn undertakes significant work for Boston Scientific, which he is currently representing in a series of cases in the District of Delaware against Nevro Corp regarding patents relating to spinal cord stimulation therapy; and for 3M Company and 3M Innovative Properties, for which he recently successfully denied institution of an inter partes review in a dispute in the dental composite space. Commercially consequential suits between competitors such as these are a daily occurrence for him and see him at his best. Paul Keller joined Allen & Overy in March 2020, giving the UK Magic Circle firm and global powerhouse a versatile patent litigator and all-round IP counsellor on the East Coast. He relishes the opportunity to do battle over emerging and disruptive technologies such as AI, the Internet of Things and autonomous driving. Potomac Law has been adding to its bench in significant ways and, in April 2020 recruited veteran technology litigator and licensing ace Michael Lennon in New York. Then, in September 2020 it unveiled Pablo Hendler as its new signing – another consummate litigator, this time with a focus on life sciences and medical devices. The leader of Simpson Thacher’s IP practice, Lori Lesser is one of New York’s best patent and technology transactions lawyers; privacy and cybersecurity are further strings to her bow. Foley Hoag bolstered its patent litigation offering in June 2020 with the arrival of Jeffrey Lewis, a seasoned life sciences litigator with a deft counselling and licensing touch. Thomas Meloro chairs the IP department at Willkie Farr & Gallagher. He has long blazed a trail in the life sciences as a litigator and trial lawyer. Lucas & Mercanti founding partner Michael Mercanti keeps his ear to the ground in clients’ markets and leverages his understanding of the competitive life sciences landscape to design and implement effective global strategies. For generic pharmaceutical companies, Deepro Mukerjee is a linchpin of success in Hatch-Waxman litigation, but adds terrific value as an all-round strategic adviser, too. He co-leads Katten’s patent litigation practice. Michael Murray is a fresh face at FisherBroyles. The former Winston & Strawn lawyer is a gifted litigator and trial lawyer who has spent decades pressing his clients’ advantage in all key forums. A leader in Vinson & Elkins’s IP litigation and commercial disputes practices, Hilary Preston designs and executes clever defence strategies for multinationals such as Japan Display, which she recently represented in three patent infringement lawsuits filed by Vista Peak Ventures in the Eastern District of Texas involving patents directed to LCD technology. David Radulescu is never thrown off his trial game: he is highly experienced, supremely confident on the technical subject matter – he’s an authority on the subject of semiconductors – and extremely committed. He founded patent litigation boutique Radulescu LLP. IP commercialisation is the specialist subject of Harry Rubin, Kramer Levin’s technology and IP transactions chair. He distinguishes himself as a global thinker and deal closer, and a font of insight and analysis on fintech matters. Arun Subramanian wears the colours of Susman & Godfrey and does the elite trial firm proud with his poised performances. He and Texas partner Joe Grinstein are representing Personalized Media Communications in a series of Eastern District of Texas cases against streaming media providers Google, Netflix and Akamai. Clifford Ulrich joined Carter De Luca in 2020, significantly amping up the firm’s prosecution, PTAB and strategic counselling practice. The former Kenyon & Kenyon and, later, Hunton Andrews Kurth partner is a veteran in the post-grant space, with experience representing petitioners and patent owners. Francisco Villegas took his talents from Cohen & Gresser to Armstrong Teasdale in September 2019. An intuitive litigator, Villegas also has a sharpened transactional skillset that he uses to support and oversee diverse corporate and IP commercialisation deals. A hugely popular name in the life sciences, Holland & Knight’s Charles Weiss has as good a handle on industry issues as any patent lawyer. This stems from his engagement in high-level litigation as well as transactional work and deep scientific, regulatory and business know-how.

Individuals: litigation

  • Peter J Armenio PC - Quinn Emanuel Urquhart & Sullivan LLP
  • Gregory S Arovas - Kirkland & Ellis LLP
  • Garrard R Beeney - Sullivan & Cromwell LLP
  • Paul A Bondor - Desmarais LLP 
  • F Dominic Cerrito - Quinn Emanuel Urquhart & Sullivan LLP
  • Robert V Cerwinski - Goodwin Procter LLP
  • Evan R Chesler - Cravath, Swaine & Moore LLP 
  • Dominick Conde - Venable LLP
  • Edward J DeFranco - Quinn Emanuel Urquhart & Sullivan LLP
  • John M Desmarais - Desmarais LLP 
  • Dimitrios T Drivas - White & Case LLP 
  • Gerald J Flattmann Jr - King & Spalding LLP
  • Christopher J Gaspar - Milbank LLP
  • Nicholas Groombridge - Paul Weiss Rifkind Wharton & Garrison LLP
  • Robert J Gunther - WilmerHale
  • Edgar H Haug - Haug Partners LLP 
  • Elizabeth J Holland - Goodwin Procter LLP
  • Keith R Hummel - Cravath, Swaine & Moore LLP 
  • Josh Krevitt - Gibson Dunn & Crutcher LLP
  • Lisa B Pensabene - O’Melveny & Myers LLP
  • E Joshua Rosenkranz - Orrick, Herrington & Sutcliffe LLP
  • Kathleen M Sullivan - Quinn Emanuel Urquhart & Sullivan LLP
  • Errol B Taylor - Milbank LLP
  • Bruce M Wexler - Paul Hastings LLP
  • Mark J Abate - Goodwin Procter LLP
  • Robert A Appleby - Kirkland & Ellis LLP
  • Jim Badke - Sidley Austin LLP
  • David K Barr - Arnold & Porter Kaye Scholer LLP
  • David Bassett - WilmerHale
  • Matthew Becker - Axinn, Veltrop & Harkrider LLP 
  • Scott J Bornstein - Greenberg Traurig LLP
  • Sandra A Bresnick - Quinn Emanuel Urquhart & Sullivan LLP
  • Daniel G Brown - Latham & Watkins LLP
  • Patricia Carson - Kirkland & Ellis LLP
  • James W Dabney - Hughes Hubbard & Reed LLP
  • Daniel P DiNapoli - Arnold & Porter Kaye Scholer LLP
  • Eric W Dittmann - Paul Hastings LLP
  • Richard Erwine - Quinn Emanuel Urquhart & Sullivan LLP
  • Lisa Ferri - Mayer Brown
  • Porter F Fleming - Haug Partners LLP 
  • John Flock - Hunton Andrews Kurth LLP
  • Mark Hannemann - Shearman & Sterling LLP 
  • David Hecht - Hecht Partners
  • Katherine A Helm - Dechert LLP
  • Benjamin Hershkowitz - Gibson Dunn & Crutcher LLP
  • Colleen Tracy James - Quinn Emanuel Urquhart & Sullivan LLP
  • Alan S Kellman - Desmarais LLP 
  • Chad Landmon - Axinn, Veltrop & Harkrider LLP 
  • Michael J Lennon - Potomac Law Group
  • Ira J Levy - Goodwin Procter LLP
  • Jeffrey ID Lewis - Foley Hoag
  • Robert Maier - Baker Botts LLP
  • Thomas R Makin - Shearman & Sterling LLP 
  • David R Marriott - Cravath, Swaine & Moore LLP 
  • Jonas R McDavit - Desmarais LLP 
  • Kevin X McGann - Fenwick & West LLP
  • Thomas J Meloro - Willkie Farr & Gallagher LLP
  • John J Molenda - Steptoe & Johnson LLP
  • Deepro R Mukerjee - Katten Muchin Rosenman LLP
  • Clement Naples - Latham & Watkins LLP
  • Douglas R Nemec - Skadden Arps Slate Meagher & Flom LLP
  • Raymond N Nimrod - Quinn Emanuel Urquhart & Sullivan LLP
  • John Normile - Jones Day
  • Catherine Nyarady - Paul Weiss Rifkind Wharton & Garrison LLP
  • Jeffrey Oelke - Fenwick & West LLP
  • Thomas Pease - Quinn Emanuel Urquhart & Sullivan LLP
  • Chad Peterman - Paul Hastings LLP
  • Filko Prugo - Ropes & Gray LLP
  • Stephen S Rabinowitz - Dechert LLP
  • David C Radulescu - Radulescu LLP
  • Paul Ragusa - Baker Botts LLP
  • Preston K Ratliff II - Paul Hastings LLP
  • Scott K Reed - Venable LLP
  • Daniel L Reisner - Arnold & Porter Kaye Scholer LLP
  • P Anthony Sammi - Skadden Arps Slate Meagher & Flom LLP
  • Michael P Sandonato - Venable LLP
  • Robert C Scheinfeld - Baker Botts LLP
  • James Shalek - Proskauer Rose LLP
  • Neil Sirota - Baker Botts LLP
  • Brian V Slater - Haug Partners LLP 
  • William E Solander - Venable LLP
  • Richard J Stark - Cravath, Swaine & Moore LLP 
  • Aaron Stiefel - Arnold & Porter Kaye Scholer LLP
  • Eric Alan Stone - Paul Weiss Rifkind Wharton & Garrison LLP
  • Daniel J Thomasch - Gibson Dunn & Crutcher LLP
  • Bryan Vogel - Robins Kaplan LLP
  • Charles A Weiss - Holland & Knight LLP
  • Elizabeth Stotland Weiswasser - Weil Gotshal & Manges LLP
  • Jennifer H Wu - Paul Weiss Rifkind Wharton & Garrison LLP
  • Gary Abelev - Hunton Andrews Kurth LLP
  • Allison Altersohn - King & Spalding LLP
  • Isaac Ashkenazi - Paul Hastings LLP
  • Michael Autuoro - Fish & Richardson
  • Jonathan D Ball - Greenberg Traurig LLP
  • Edmond R Bannon - Fish & Richardson
  • James S Blank - Baker McKenzie
  • Christopher Borello - Venable LLP
  • Karen Bromberg - Cohen & Gresser LLP
  • Joseph A Calvaruso - Orrick, Herrington & Sutcliffe LLP
  • Angus Chen - Quinn Emanuel Urquhart & Sullivan LLP
  • Arlene L Chow - Latham & Watkins LLP
  • Natalie C Clayton - Alston & Bird LLP
  • Alan Clement - Locke Lord LLP
  • Rose Cordero Prey - Greenberg Traurig LLP
  • Sona De - Sidley Austin LLP
  • Anish Desai - Weil Gotshal & Manges LLP
  • Evan Diamond - King & Spalding LLP
  • Bindu Donovan - Desmarais LLP 
  • Peter N Fill - Locke Lord LLP
  • Todd M Friedman - Kirkland & Ellis LLP
  • Ching-Lee Fukuda - Sidley Austin LLP
  • Adam Gahtan - Fenwick & West LLP
  • Raj Gandesha - White & Case LLP 
  • Elizabeth Gardner - Robins Kaplan LLP
  • Melvin C Garner - Leason Ellis LLP
  • Frank M Gasparo - Venable LLP
  • Sharonmoyee Goswami - Cravath, Swaine & Moore LLP 
  • Vishal C Gupta - Steptoe & Johnson LLP
  • Dustin F Guzior - Sullivan & Cromwell LLP
  • Yung-Hoon (Sam) Ha - Desmarais LLP 
  • Yung-Hoon (Sam) Ha - Desmarais LLP 
  • Alison Hanstead - White & Case LLP 
  • Christopher J Harnett - Maynard Cooper & Gale PC
  • Jonathan A Harris - Akin Gump
  • Jeanne M Heffernan - Kirkland & Ellis LLP
  • Pablo D Hendler - Potomac Law Group
  • Philip Hirschhorn - Panitch Schwarze Belisario & Nadel LLP
  • Robert M Isackson - Leason Ellis LLP
  • Charlotte Jacobsen - Ropes & Gray LLP
  • Patrice P Jean - Hughes Hubbard & Reed LLP
  • Michael P Kahn - Akin Gump Strauss Hauer & Feld LLP
  • Allan A Kassenoff - Greenberg Traurig LLP
  • Paul Keller - Allen & Overy LLP
  • Todd L Krause - Desmarais LLP 
  • Gene W Lee - Perkins Coie LLP
  • Noah M Leibowitz - Dechert LLP
  • Jane Love - Gibson Dunn & Crutcher LLP
  • Joseph A Loy - Kirkland & Ellis LLP
  • Yuval Marcus - Leason Ellis LLP
  • William J McCabe - Perkins Coie LLP
  • Richard McCormick - Mayer Brown
  • Michael M Murray - FisherBroyles
  • Brian W Nolan - Mayer Brown
  • Christopher Noyes - WilmerHale
  • Karim Z Oussayef - Desmarais LLP 
  • Tamir Packin - Desmarais LLP 
  • Krishnan Padmanabhan - Winston & Strawn LLP
  • Steven Pepe - Ropes & Gray LLP
  • Richard C Pettus - Greenberg Traurig LLP
  • Hilary L Preston - Vinson & Elkins LLP
  • Joshua L Raskin - Greenberg Traurig LLP
  • Brian Rosenthal - Gibson Dunn & Crutcher LLP
  • Hassen Sayeed - O’Melveny & Myers LLP
  • David Silverstein - Axinn, Veltrop & Harkrider LLP 
  • Kenneth H Sonnenfeld - Ballard Spahr LLP
  • Arun Subramanian - Susman Godfrey LLP
  • Jen Tempesta - Baker Botts LLP
  • James Trainor - Fenwick & West LLP
  • Robert W Trenchard - Gibson Dunn & Crutcher LLP
  • Clifford A Ulrich - Carter De Luca
  • Alexandra Valenti - Goodwin Procter LLP
  • Francisco A Villegas - Armstrong Teasdale
  • Baldassare Vinti - Proskauer Rose LLP
  • Scott T Weingaertner - White & Case LLP 
  • Calvin Wingfield - Goodwin Procter LLP
  • Ha Kung Wong - Venable LLP
  • Vanessa Yen - King & Spalding LLP
  • Guy Yonay - Pearl Cohen Zedek Latzer Baratz
  • Michael T Zoppo - Fish & Richardson
  • Mark Hannemann - Shearman & Sterling LLP 
  • Mike Imbacuan - Greenberg Traurig LLP
  • Thomas R Makin - Shearman & Sterling LLP 

Individuals: prosecution

  • Dianna El Hioum - Fox Rothschild LLP 
  • Carl A Morales PhD - Dechert LLP
  • Samuel B Abrams - Dechert LLP
  • Adriane M Antler - Jones Day
  • Jonathan D Ball - Greenberg Traurig LLP
  • Elizabeth Barnhard - Leason Ellis LLP
  • Samuel Borodach - Fish & Richardson
  • Jack Brennan - Fish & Richardson
  • Margaret Brivanlou - Ballard Spahr LLP
  • Daniel R Brownstone - Fenwick & West LLP
  • Laura C Brutman - Schiff Hardin LLP
  • Susie S Cheng - Leason Ellis LLP
  • Mark S Cohen - Pearl Cohen Zedek Latzer Baratz
  • Michael A Davitz - Leason Ellis LLP
  • Edward J Ellis - Leason Ellis LLP
  • Ivor R Elrifi - Cooley LLP
  • Peter N Fill - Locke Lord LLP
  • Melvin C Garner - Leason Ellis LLP
  • Christopher Glynn - Fox Rothschild LLP
  • Joseph M Guiliano - Haley Guiliano LLP
  • James F Haley Jr - Haley Guiliano LLP
  • Daniel Hulseberg - Baker Botts LLP
  • Oleg Kaplun - Fay Kaplun & Marcin LLP
  • Matthew Kaufman - Leason Ellis LLP
  • David Leason - Leason Ellis LLP
  • Steve Lendaris - Baker Botts LLP
  • Ying Li - Steptoe & Johnson LLP
  • Janet MacLeod - Fox Rothschild LLP
  • Karen Mangasarian - Haley Guiliano LLP
  • Michael Mercanti - Lucas & Mercanti LLP
  • Gerard Messina - Norton Rose Fulbright
  • Zeev Pearl - Pearl Cohen Zedek Latzer Baratz
  • Paul Ragusa - Baker Botts LLP
  • Robert C Scheinfeld - Baker Botts LLP
  • Pejman Sharifi - Winston & Strawn LLP
  • Deborah A Somerville - Fox Rothschild LLP
  • Kenneth H Sonnenfeld - Ballard Spahr LLP
  • Clifford A Ulrich - Carter De Luca
  • Tony Zhang - Fish & Richardson

Individuals: transactions

  • Garrard R Beeney - Sullivan & Cromwell LLP
  • Michael A Epstein - Weil Gotshal & Manges LLP
  • David J Kappos - Cravath, Swaine & Moore LLP 
  • Lori Lesser - Simpson Thacher & Bartlett LLP
  • Stuart D Levi - Skadden Arps Slate Meagher & Flom LLP
  • Jeffrey Osterman - Weil Gotshal & Manges LLP
  • Charan J Sandhu - Weil Gotshal & Manges LLP
  • Charles A Weiss - Holland & Knight LLP
  • Carl A Morales PhD - Dechert LLP
  • Jordan Altman - Shearman & Sterling LLP 
  • Jordan Altman - Shearman & Sterling LLP 
  • Mehdi Ansari - Sullivan & Cromwell LLP
  • Frank J Azzopardi - Davis Polk & Wardwell LLP
  • Elizabeth Barnhard - Leason Ellis LLP
  • David Bauer - Davis Polk & Wardwell LLP
  • Adam Chernichaw - Allen & Overy LLP 
  • Mark S Cohen - Pearl Cohen Zedek Latzer Baratz
  • Jennifer B Coplan - Sidley Austin LLP
  • Ivor R Elrifi - Cooley LLP
  • Jose A Esteves - Skadden Arps Slate Meagher & Flom LLP
  • John Evangelakos - Sullivan & Cromwell LLP
  • Lisa Ferri - Mayer Brown
  • Adam H Golden - Hogan Lovells
  • Daryn A Grossman - Proskauer Rose LLP
  • Arlene Arin Hahn - White & Case LLP 
  • Erin Hanson - White & Case LLP 
  • Daniel Hulseberg - Baker Botts LLP
  • Jeffrey C Johnson - Pryor Cashman LLP
  • David Leason - Leason Ellis LLP
  • Noah M Leibowitz - Dechert LLP
  • Steve Lendaris - Baker Botts LLP
  • Michael J Lennon - Potomac Law Group
  • David MacDonald - Kirkland & Ellis LLP
  • Brian W Nolan - Mayer Brown
  • Zeev Pearl - Pearl Cohen Zedek Latzer Baratz
  • Thomas Pease - Quinn Emanuel Urquhart & Sullivan LLP
  • Paul Ragusa - Baker Botts LLP
  • Harry Rubin - Kramer Levin Naftalis & Frankel LLP
  • Alicia Russo - Venable LLP
  • Resa K Schlossberg - Skadden Arps Slate Meagher & Flom LLP
  • Pejman Sharifi - Winston & Strawn LLP
  • Kenneth H Sonnenfeld - Ballard Spahr LLP
  • Samuel Waxman - Paul Hastings LLP
  • Ha Kung Wong - Venable LLP